Source: International Congress 2016 – IPF: from pathogenesis to treatment II



Rating:

Share or cite this content

Citations should be made in the following way:
Radwa Elhefny (Cairo, Egypt), Radwa Elhefny, Sabah Ahmed, Marwa Moawad, Mona Abdullatif. Is toll like receptor 4 a common pathway hypothesis for development of lung cancer and idiopathic pulmonary fibrosis?. Eur Respir J 2016; 48: Suppl. 60, 2097

Member's Comments

No comment yet.

Related content which might interest you: Lung cancer in patients with idiopathic pulmonary fibrosis: Clinical characteristics and impact on survival Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 COPD; IPF; lung cancer in same individual: Can it be called 'AJMERITES SYNDROME? Source: Annual Congress 2013 –COPD treatment and others Year: 2013 Pemetrexed in advanced non-small cell lung cancer patients with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Advances in the therapy of lung cancer Year: 2013 Neoplasia in patients with ILD; shortened survival Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Local and systemic neutrophilic inflammation in patients with lung cancer and chronic obstructive pulmonary disease Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer Year: 2013 Incidence, outcomes and risk factors for neoplasms in explanted lungs Source: International Congress 2016 – Long-term outcomes of lung transplantation Year: 2016 Assessment of nutritional status in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 Loss of PTEN induced lung fibroblasts exhibiting similar pathogenic features to cancer cells in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Possible indication for surgical resection of lung cancer associated with combined pulmonary fibrosis and emphysema (CPFE) Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Does apoptosis evasion only affect fibroblasts from idiopathic pulmonary fibrosis? Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013? Year: 2013 Idiopathic pulmonary fibrosis: Gender differences in survival and functional decline. A retrospective study Source: International Congress 2016 – IPF: from pathogenesis to treatment I Year: 2016 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 What (and how) do we attain by performing surgical lung biopsy for interstitial lung disease? Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Club cell secretory protein-CC16 is increased in idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD pathogenesis Year: 2016 The effect of pirfenidone on impaired lung function in patients with idiopathic pulmonary fibrosis (IPF) from Czech IPF registry Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Clinical profile of idiopathic pulmonary fibrosis with lung cancer Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis? Year: 2011 The impact of chronic obstructive pulmonary disease on survival of the patients with small-cell lung cancer Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015 Role of dendritic cells in pulmonary fibrosis in mice Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 T-cell pathways in lung tissue of patients with advanced COPD and IPF requiring lung transplantation Source: International Congress 2016 – Mechanisms of disease Year: 2016 Lung cancer as a comorbidity in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Pulmonary manifestations of systemic diseases Year: 2012